186 related articles for article (PubMed ID: 36528469)
1. Ferroptosis Biomarkers for Predicting Prognosis and Immunotherapy Efficacy in Adrenocortical Carcinoma.
Shen C; Wang Y
Arch Med Res; 2023 Jan; 54(1):45-55. PubMed ID: 36528469
[TBL] [Abstract][Full Text] [Related]
2. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
3. Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma.
Xu F; Guan Y; Zhang P; Xue L; Ma Y; Gao M; Chong T; Ren BC
BMC Endocr Disord; 2022 May; 22(1):130. PubMed ID: 35568842
[TBL] [Abstract][Full Text] [Related]
4. Identification of Molecular Subtypes and Prognostic Characteristics of Adrenocortical Carcinoma Based on Unsupervised Clustering.
Zhang Y; Zhang C; Li K; Deng J; Liu H; Lai G; Xie B; Zhong X
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895143
[TBL] [Abstract][Full Text] [Related]
5. Identification of immune-related biomarkers in adrenocortical carcinoma: Immune-related biomarkers for ACC.
Peng Y; Song Y; Ding J; Li N; Zhang Z; Wang H
Int Immunopharmacol; 2020 Nov; 88():106930. PubMed ID: 32919215
[TBL] [Abstract][Full Text] [Related]
6. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of a tumor mutation burden-related signature combined with immune microenvironment infiltration in adrenocortical carcinoma.
Luo Y; Chen Q; Lin J
Math Biosci Eng; 2022 May; 19(7):7055-7075. PubMed ID: 35730296
[TBL] [Abstract][Full Text] [Related]
8. Identification of the ferroptosis regulator HELLS with prognostic value for adrenocortical carcinoma based on integrated analysis and experimental validation.
Liu Z; Xie Y; Liu S; Shen S; Zhu Y; Gou Q
Gland Surg; 2023 Sep; 12(9):1251-1270. PubMed ID: 37842529
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of an m6A RNA Methylation Regulators-Based Signature for Predicting the Prognosis of Adrenocortical Carcinoma.
Shen C; Liu J; Yang X; Jiao W; Wang Y
Front Endocrinol (Lausanne); 2021; 12():568397. PubMed ID: 33692753
[TBL] [Abstract][Full Text] [Related]
10. Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma.
Xu W; Li H; Hameed Y; Abdel-Maksoud MA; Almutairi SM; Mubarak A; Aufy M; Alturaiki W; Alshalani AJ; Mahmoud AM; Li C
Oncol Res; 2023; 31(5):819-831. PubMed ID: 37547754
[TBL] [Abstract][Full Text] [Related]
11. Identification of prognostic genes in adrenocortical carcinoma microenvironment based on bioinformatic methods.
Li X; Gao Y; Xu Z; Zhang Z; Zheng Y; Qi F
Cancer Med; 2020 Feb; 9(3):1161-1172. PubMed ID: 31856409
[TBL] [Abstract][Full Text] [Related]
12. Ferroptosis-based molecular prognostic model for adrenocortical carcinoma based on least absolute shrinkage and selection operator regression.
Lin C; Hu R; Sun F; Liang W
J Clin Lab Anal; 2022 Jun; 36(6):e24465. PubMed ID: 35500219
[TBL] [Abstract][Full Text] [Related]
13. Expression patterns and prognostic value of m6A RNA methylation regulators in adrenocortical carcinoma.
Fu Y; Sun S; Bi J; Kong C; Yin L
Medicine (Baltimore); 2021 Mar; 100(10):e25031. PubMed ID: 33725886
[TBL] [Abstract][Full Text] [Related]
14. Identification of an immune-related gene signature as a prognostic target and the immune microenvironment for adrenocortical carcinoma.
Xu C; Qin C; Jian J; Peng Y; Wang X; Chen X; Wu D; Song Y
Immun Inflamm Dis; 2022 Sep; 10(9):e680. PubMed ID: 36039643
[TBL] [Abstract][Full Text] [Related]
15. Adrenocortical Carcinoma Steroid Profiles:
Muzzi JCD; Magno JM; Cardoso MA; de Moura J; Castro MAA; Figueiredo BC
Front Endocrinol (Lausanne); 2021; 12():672319. PubMed ID: 34194394
[TBL] [Abstract][Full Text] [Related]
16. Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment.
Baechle JJ; Hanna DN; Sekhar KR; Rathmell JC; Rathmell WK; Baregamian N
Surgery; 2022 Jan; 171(1):111-118. PubMed ID: 34261605
[TBL] [Abstract][Full Text] [Related]
17. Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma.
Chen Y; Chen J; Shi Y; Ling X; Fang S; Zhong C; Liu F; Zhong W; Bi X; Dong Z; Lu J
Endocr Relat Cancer; 2024 Mar; 31(3):. PubMed ID: 38224097
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk of ferroptosis regulators and tumor immunity in pancreatic adenocarcinoma: novel perspective to mRNA vaccines and personalized immunotherapy.
Shi Y; Wang Y; Dong H; Niu K; Zhang W; Feng K; Yang R; Zhang Y
Apoptosis; 2023 Oct; 28(9-10):1423-1435. PubMed ID: 37369808
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive pan-cancer analysis and the regulatory mechanism of AURKA, a gene associated with prognosis of ferroptosis of adrenal cortical carcinoma in the tumor micro-environment.
Lu K; Yuan X; Zhao L; Wang B; Zhang Y
Front Genet; 2022; 13():996180. PubMed ID: 36685952
[No Abstract] [Full Text] [Related]
20. Integrative analysis of the molecular mechanisms, immunological features and immunotherapy response of ferroptosis regulators across 33 cancer types.
Tang B; Yan R; Zhu J; Cheng S; Kong C; Chen W; Fang S; Wang Y; Yang Y; Qiu R; Lu C; Ji J
Int J Biol Sci; 2022; 18(1):180-198. PubMed ID: 34975326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
